Clinical Trial Update: Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study) [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing insulin glargine (Lantus) with a sulfonylurea for beta-cell function in type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Glargine (insulin glargine)
• Sulfonylurea (class)

Snippet

Sponsor: Sanofi | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED